Ozempic Feet: Fat Pad Loss, Foot Pain and the Evidence

Ozempic feet is an online nickname for sore, bony-feeling feet after weight loss on semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound). The usual explanation is that the fat pads cushioning the heel and the ball of the foot thin out as body fat falls. That idea is plausible, but it rests on podiatrists’ observations and patient reports: no clinical trial has measured foot fat pads on GLP-1 medicines, and no FDA label lists foot changes. Weight loss also takes load off the feet, and one observational study even linked semaglutide with less heel pain. Supportive, cushioned shoes are a sensible first step, and persistent pain, or any foot problem if you have diabetes, belongs with a podiatrist.

Peptide Labs does not sell Ozempic, Wegovy, Mounjaro, Zepbound or any prescription drug. This article summarizes FDA labels and published research. For a related body-shape change, see Ozempic butt.

What are Ozempic feet?

People use the term for several complaints: heels or the balls of the feet that feel bruised or “bony” when walking barefoot, shoes that suddenly fit differently, and feet that look thinner with more visible veins and tendons. Podiatry clinics and health websites began using the phrase after “Ozempic face” became widely known. Like our article on Ozempic face explains for the face, the underlying idea is fat loss in an area where fat serves a purpose.

The plantar fat pad and fat pad atrophy

Under the heel sits a specialized pad of fat packed into small chambers walled off by tough collagen and elastic fibers. A 2022 scoping review in the Journal of Foot and Ankle Research describes it as a cushion that absorbs shock and spreads pressure while walking. A similar pad sits under the ball of the foot. When these pads thin or lose their structure, often called fat pad atrophy or heel fat pad syndrome, the heel loses shock absorption and walking can hurt.

The review lists proposed causes as aging, injury, repeated or prolonged overloading (for example in endurance runners), overweight, poor footwear, steroid injections and conditions such as diabetes or rheumatic disease. Weight loss is not on that list. Pain from fat pad syndrome tends to be worse after long periods of standing, at night or in both heels, while sharp first-step pain in the morning points more toward plantar fasciitis. The authors call the research sparse and note that no randomized trials of heel cups or taping exist.

Is there evidence for GLP-1 foot pain?

Not much, and what exists points in different directions. The table summarizes it.

That 2025 study, from two hospitals in China and published in the International Journal of Surgery, followed 2,902 adults with chronic heel pain for at least two years. The 92 people using semaglutide reported larger improvements in foot pain, and their plantar fascia thickened more slowly. It did not measure fat pads, and the authors note bias risks, unbalanced groups and missing data on activity and diet. It cannot prove the drug helped, but it is a reminder that carrying less weight often eases foot strain.

So far, GLP-1 foot pain blamed on fat pad loss is a reasonable hypothesis without direct evidence. Sore feet can also come from new exercise routines, more walking, worn-out shoes or plantar fasciitis.

Numbness, burning and tingling: a different issue

Burning, tingling or numb feet are not the same as a thin fat pad. In people with diabetes, these symptoms often reflect diabetic nerve damage (neuropathy). The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) explains that diabetes can damage nerves and reduce blood flow in the feet, so injuries may go unnoticed and heal slowly. Neuropathy is a complication of diabetes, not a known effect of GLP-1 medicines.

The Wegovy label (June 2026) does list dysesthesia, a group of altered skin sensations that includes tingling, burning and sensitive skin, and says it became more common at higher strengths. It is not described as a foot problem, but new or unusual sensations anywhere are worth reporting to your prescriber. Other reported effects are collected in our guide to GLP-1 medicine side effects.

Looking after your feet during weight loss

The American Podiatric Medical Association (APMA) suggests choosing shoes by foot type, with cushioned shoes and a softer midsole for people whose feet absorb shock poorly. General steps that many people find helpful:

• Wear supportive, cushioned shoes indoors as well as outdoors if bare floors hurt, and replace worn-out pairs.
• Recheck shoe size; feet can change shape as weight changes.
• Consider an over-the-counter cushioned insert or heel cup. APMA says inserts can help with foot and leg pain but cannot correct structural foot problems.
• Build up new walking or running gradually, and include strength training for the legs. Keeping muscle matters across the body; see muscle loss on GLP-1 medicines.
• If you have diabetes, check your feet every day and wear shoes and socks to protect them, as NIDDK advises.

When to see a podiatrist

APMA advises seeing a podiatrist for serious pain or discomfort, and says an over-the-counter insert may not suit people with diabetes or circulation problems. NIDDK adds that people with diabetes can have foot problems without feeling pain. Get care promptly for:

• A cut, blister or bruise that does not start to heal after a few days.
• Redness, warmth, swelling, pus or other signs of infection.
• Heel or foot pain that lasts more than a few weeks or keeps you from walking normally.
• New numbness, burning or tingling, especially with diabetes.
• Color changes, cold feet or sores, which can signal poor circulation.

Frequently Asked Questions

Peptide Labs does not sell GLP-1 medicines or any prescription drug. This article is general information, not medical advice. Read the Medication Guide that comes with a prescription, and ask a pharmacist or prescriber how this information applies to you.

Last reviewed October 2026.

Related guides: Ozempic Face: What It Is and What the Evidence Says, Ozempic Muscle Loss: What the Body-Scan Data Show, GLP-1 Side Effects: What Every GLP-1 Drug Label Warns About.